10-K: Fortrea Holdings Inc. Details Capital Structure and Governance in 10-K Filing

Fortrea Holdings Inc.'s 10-K filing outlines its capital stock structure, governance, and risk factors as a newly independent public company.

Summary

• Fortrea Holdings Inc.'s 10-K filing details the company's capital structure, consisting of 265,000,000 shares of common stock and 30,000,000 shares of preferred stock, both with a par value of $0.001 per share.
• The document explains that common stockholders have one vote per share and are entitled to a ratable share of assets upon liquidation after preferred stockholders.
• The board of directors has the authority to issue preferred stock with varying rights and preferences, including voting powers, redemption provisions, dividend rates, and conversion rights.
• The filing also outlines anti-takeover provisions, such as a staggered board, no cumulative voting, and a supermajority vote requirement to amend certain bylaws and charter provisions until 2028.
• Fortrea's common stock trades on NASDAQ under the symbol FTRE, and American Stock Transfer & Trust Company serves as the transfer agent.
• The company completed its spin-off from Laboratory Corporation of America Holdings on June 30, 2023, and its common stock began trading on July 3, 2023.
• As of March 11, 2024, there were 89.4 million shares of common stock outstanding.
• The document includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially from those projected due to various risks and uncertainties.
• Fortrea operates in two segments: Clinical Services and Enabling Services, with a global team of approximately 18,000 employees across 90 countries.
• The company's clinical development business has conducted over 5,850 phase I through IV clinical trial projects involving more than 1,000,000 subjects in the past five years.
• The clinical development market is estimated to be $100 billion in 2022, with Fortrea's addressable market at $35 billion.
• The document highlights key trends such as increasing pharmaceutical R&D spend, expanding scope of CRO capabilities, and elevated outsourcing levels.
• Fortrea's competitive strengths include its extensive history, diversified customer base, global relationships, access to clinical data, and expertise across therapeutic areas.
• The company's growth strategy focuses on scientific expertise, site support, global scale, technology investment, and customer partnerships.
• The filing also details the company's human capital, intellectual property, government regulations, and risk factors.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While it highlights Fortrea's strengths and growth strategies, it also acknowledges significant risks and challenges, including financial and operational hurdles. The results for 2023 were worse than 2022. The sentiment is neutral to slightly negative due to the inherent risks and the worse than expected results.

Positives

• Fortrea has a strong history of over 30 years in clinical development services.
• The company has a large and diversified customer base, including both large and emerging pharmaceutical, biotechnology, and medical device organizations.
• Fortrea has global and stable customer relationships, with top customers consistently representing a significant portion of total revenue.
• The company has access to actionable clinical data and insights, which it intends to prioritize.
• Fortrea has expertise across a wide range of therapeutic areas, including rapidly growing scientific areas.
• The company has a flexible approach to serving customers through Full Service, Functional Service Provider, and Hybrid delivery models.
• Fortrea is committed to increasing the diversity of patient populations within clinical trials.
• The company has a strong focus on employee engagement and development.
• Fortrea has a market leading position in clinical pharmacology studies.

Negatives

• The company is subject to anti-takeover provisions that may discourage or make more difficult an attempt to acquire control of Fortrea.
• The company is dependent on third parties to provide services critical to its business.
• Fortrea's business is subject to a number of risks inherent to the industry, including customer funding and the ability to generate new business.
• The company's backlog may not be indicative of future revenues.
• The company may experience fluctuations in its effective income tax rate.
• The company is subject to various legal and regulatory risks.
• The company is subject to risks associated with strategic transactions, including acquisitions and divestitures.
• The company is subject to technology and cybersecurity risks.
• The company is subject to financial risks, including debt and debt covenant requirements.
• The company is subject to general business risks, including macroeconomic trends and natural disasters.

Risks

• The company's business may be adversely affected if it does not generate a large number of net new business awards, or if awards are delayed, terminated, or reduced in scope.
• The company's business might suffer if it is unable to contract with suitable investigators and recruit and enroll patients for clinical trials.
• International operations could subject the company to additional risks and expenses.
• Customer or therapeutic area concentration may have a material adverse effect on the company's business.
• Customers may experience insufficient funding to complete their clinical trials.
• The company's backlog might not be indicative of future revenues.
• An inability to attract and retain experienced and qualified personnel could adversely affect the business.
• The company depends on third parties to provide services critical to its business.
• The company's accounting, enterprise resource planning, and other management systems may not be adequately prepared to meet financial reporting requirements.
• Failure to comply with regulations of pharmaceutical and medical device regulatory agencies could result in sanctions.
• Changes in government regulation could decrease the need for certain services.
• Failure to comply with privacy and security laws could result in fines and penalties.
• A failure to identify and successfully close strategic transactions could have a material adverse effect on the business.
• The pending divestiture of certain assets may not close on time or at all.
• Failure to maintain the security of customer-related information could damage the company's reputation.
• Failure in IT systems may harm the company.
• Security breaches and unauthorized access to data could harm the company's reputation.
• Failure to comply with contractual requirements could result in claims and/or remedies against the company.
• Contract research services create liability risk.
• Failure to obtain, maintain, and enforce intellectual property rights could adversely affect the company.
• Changes in tax rates, laws, or regulations may adversely impact financial results.
• The company is subject to continuing contingent liabilities as a result of the spin-off.
• The company bears financial risk for contracts that may be underpriced, subject to cost overruns, delayed, or terminated.
• The company's revenues depend on the pharmaceutical, biotechnology, and medical device industries.
• Foreign currency fluctuations could have an adverse effect on the business.
• Debt and debt covenant requirements may limit cash flow available to invest in the business.
• The company may not be able to access the capital and credit markets on favorable terms.
• The company is subject to a wide range of factors that impact global businesses, including macroeconomic trends and natural disasters.
• Failure to establish and maintain effective internal control over financial reporting could materially and adversely affect the company.
• Anti-takeover provisions in charter documents and Delaware law could discourage, delay, or prevent a change in control.

Future Outlook

The company expects to continue to strategically invest in markets to meet the needs of its customers and the demands of the global clinical trial landscape. The company also plans to continue to invest in its capabilities, its ability to generate insights through data and analytics, reduce cost, and increase the speed and efficiency of clinical trial execution to enhance the quality of its offerings for its customers.

Management Comments

• Fortrea combines decades of domain expertise with the nimbleness required to meet market demand for flexible engagements with large and small customers, delivering solutions that bring life-changing treatments to patients faster and creating value for all stakeholders.
• We believe we are well positioned to leverage our global scale, access to clinical data-driven insights, industry network, and decades of experience to bring customers distinctive, expert solutions.
• We believe that our commitment to continuous services and technology innovations combined with Fortreas customizable approach and experience across more than 20 therapeutic areas will enable us to continue to differentiate ourselves from peers in the CRO industry.

Industry Context

This announcement comes as the CRO industry is experiencing growth driven by increasing pharmaceutical and biotechnology R&D spending, expanding scope of capabilities, and elevated outsourcing levels. Fortrea is positioning itself to capitalize on these trends by offering flexible and tailored solutions to its customers.

Comparison to Industry Standards

• Fortrea's focus on oncology, CNS, and rare diseases aligns with industry trends in high-growth therapeutic areas.
• The company's emphasis on technology and data utilization is consistent with the industry's move towards digital and decentralized clinical trials.
• Fortrea's global presence and scale are comparable to other large CROs, such as IQVIA and PPD.
• The company's flexible delivery models (Full Service, FSP, Hybrid) are similar to those offered by other major CROs.
• Fortrea's investment in clinical pharmacology units and cGMP pharmacies is a differentiator in the market.
• The company's focus on site relationships and patient recruitment addresses a key challenge in the clinical trial process, similar to strategies employed by other CROs.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various claims and legal actions arising in the ordinary course of business.
• The company has agreed to make concessions and provide discounts and other consideration to a customer of an estimated amount of $12.5 million as part of a multi-party solution to facilitate ongoing trials, of which $5.5 million was recorded as a reduction of revenue in 2023.

Related Party Transactions

• The company has entered into several agreements with Labcorp that govern the relationship of the parties following the Separation, including the Separation and Distribution Agreement, the Tax Matters Agreement, the Employee Matters Agreement, and the Transition Services Agreement.
• The company's combined statements of operations include costs for certain centralized functions and programs provided and administered by Labcorp that were allocated to the company.
• The company's direct costs include items purchased from Labcorp totaling $48.8 million in 2023.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance, strategic decisions, and risk factors.
• Employees may be impacted by changes in compensation, benefits, and job security.
• Customers may be impacted by the quality and availability of the company's services.
• Suppliers may be impacted by the company's purchasing decisions and payment terms.
• Creditors may be impacted by the company's debt levels and ability to repay its obligations.

Next Steps

• The company plans to continue to strategically invest in markets to meet the needs of its customers.
• Fortrea will continue to invest in its capabilities, data analytics, and efficiency of clinical trial execution.
• The company will continue to pursue strategic acquisitions to strengthen its scientific capabilities and enhance therapeutic expertise.
• Fortrea will continue to expand its small and mid-size customer base and build long-tenured partnerships.
• The company will continue to expand existing partnerships with large pharmaceutical customers and add new partnerships where there is a strong strategic alignment.

Key Dates

Keywords

Contract Research Organization, CRO, Clinical Trials, Pharmaceutical, Biotechnology, Medical Device, Clinical Development, Patient Access, Drug Development, Regulatory Affairs, Clinical Pharmacology, Data Management, Biostatistics, Oncology, Therapeutic Areas, Outsourcing, R&D, NASDAQ, FTRE, Spin-off